FDA calendar · December 2022 · built from SEC filings

PDUFA dates December 2022: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in December 2022. The FDA calendar also recorded 41 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in December 2022

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

December 2022: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Dec 2022Month disclosedMethotrexate Preservative Free (methotrexate)ALDXNDA/BLA accepted—CompletedSEC 8-K Exhibit 99.1
Dec 2022Month disclosedLUNSUMIOBIIBFDA approvalrelapsed or refractory follicular lymphomaApprovedSEC Form 10-K
Dec 2022Month disclosedREZLIDHIA (olutasidenib)RIGLFDA approval—ApprovedSEC Form 10-Q
Dec 2022Month disclosedBrexafemme (ibrexafungerp)SCYXFDA approval—ApprovedSEC Form 10-Q
Dec 2022Month disclosedHyBryte (lymphoma)SNGXNDA/BLA submission—CompletedSEC Form 10-Q
Dec 2022Month disclosedtebipenemSPRONDA/BLA accepted—CompletedSEC Form 10-K
Dec 2022Month disclosedgenericVNDAFDA approval—ApprovedSEC Form 10-K
Dec 2022Month disclosedHETLIOZ® (tasimelteon)VNDAFDA approval—ApprovedSEC Form 10-Q
December 8, 2022ZEJULA (niraparib)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
December 9, 2022VELCADE® (bortezomib)PFELabel expansion—ApprovedopenFDA Drugs@FDA
December 12, 2022Krazati (adagrasib)BMYFDA approval—ApprovedFDA Novel Drug Approvals
December 13, 2022IBRANCE® (palbociclib)PFELabel expansion—ApprovedopenFDA Drugs@FDA
December 15, 2022BENDEKA (bendamustine)PFEFDA approval—ApprovedopenFDA Drugs@FDA
December 16, 2022Vraylar (cariprazine hydrochloride)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
December 16, 2022KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
December 16, 2022IGALMI® (dexmedetomidine)PFELabel expansion—ApprovedopenFDA Drugs@FDA
December 17, 2022—MENSNDA/BLA accepted—Completedsec_424b
December 19, 2022JAKAFI (ruxolitinib)INCYLabel expansion—ApprovedopenFDA Drugs@FDA
December 20, 2022Avycaz (avibactam sodium; ceftazidime)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
December 20, 2022Simlandi (adalimumab-ryvk)ALVOComplete Response Letter—CRL issuedFDA Complete Response Letters
December 22, 2022Yeztugo® (lenacapavir)GILDFDA approval—ApprovedFDA Novel Drug Approvals
December 23, 2022Wegovy (semaglutide)NVOLabel expansion—ApprovedopenFDA Drugs@FDA
December 28, 2022NexoBrid (anacaulase)MDWDFDA approvalTo remove eschar in adults with deep partial thickness or full thickness thermal burnsApprovedFDA Novel Drug Approvals
December 28, 2022CLEER-001RKTOFDA approval—ApprovedSEC Form 10-K
December 28, 2022BRIUMVI® (ublituximab)TGTXFDA approval—ApprovedSEC Form 10-Q
December 28, 2022Briumvi (ublituximab-xiiy)TGTXFDA approvalTo treat relapsing forms of multiple sclerosisApprovedFDA Novel Drug Approvals
December 31, 2022—IBRXFDA approval—ApprovedSEC Form 10-Q

December 2022: dated readouts

DateDrugCompanyEventIndicationStatusSource
Dec 2022Month disclosedDT-216DSGNInterim readout—PositiveSEC Form 10-Q
Dec 2022Month disclosedseralutinib (GB002)GOSSTopline readout—PositiveSEC Form 10-Q
Dec 2022Month disclosedSoluspan® (betamethasone)GRCETopline readout—Met primary endpointSEC Form 10-Q
Dec 2022Month disclosedPSA-201MLTXTopline readoutactive PsAMet primary endpointSEC Form 10-Q
Dec 2022Month discloseddeucrictibant (PHA121)PHVSTopline readout—PositiveSEC 8-K Exhibit 99.1
Dec 2022Month disclosed—TARSTopline readout—PositiveSEC Form 10-K
Dec 2022Month disclosed—TARSTopline readout—PositiveSEC Form 10-Q

December 2022: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Dec 2022Month disclosedPovofortay (povorcitinib)INCYTrial start—CompletedSEC Form 10-Q
Dec 2022Month disclosedPSA-201MLTXTrial startactive PsACompletedSEC Form 10-Q
Dec 2022Month disclosedPHVS416PHVSTrial start—Completedsec_424b
Dec 2022Month disclosedRZ402RZLTTrial start—Completedsec_424b
December 31, 2022batoclimab (IMVT-1401)IMVTTrial start—CompletedSEC Form 10-Q
Dec 2022Month disclosedOV329OVIDTrial start—CompletedSEC Form 10-Q
Dec 2022Month disclosedLumvoa™ (veligrotug)VRDNTrial start—CompletedSEC Form 10-Q

Questions

What PDUFA dates are in December 2022?

0 PDUFA dates fell in December 2022. The FDA calendar also recorded 41 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.